Artesunate-amodiaquine is associated with reduced Ebola mortality
Year: 2015
Type: other
Abstract: Malaria treatment is recommended for all suspected cases of Ebola virus disease (EVD), either presumptively or based on malaria diagnosis. In Foya Ebola Management Centre (EMC), Lofa County, Liberia, the first-line anti-malarial, artemether-lumefantrine (AL), ran out for a 2-week period in August 2014. During this stock rupture, patients received artesunate-amodiaquine (ASAQ); amodiaquine is known to have anti-Ebola virus activity in vitro. We analysed routine programme data with the aim of determining the effect of malaria treatment on mortality in EVD patients.ASAQ may provide substantial protection against EVD mortality compared with AL. While more pre-clinical and clinical research is needed to understand these biologically plausible findings, health policymakers should consider recommending ASAQ for all EVD patients regardless of malaria status.
Authors: Etienne Gignoux, Andrew S Azman, Martin de Smet, Philippe Azuma, Josephus Bolongei, Moses Massaquoi, Dorian Job, Amanda Tiffany, Roberta Petrucci, Esther Sterk, Julien Potet, Motoi Suzuki, Andreas Kurth, Angela Cannas, Anne Bocquin, Thomas Strecker, Christopher Logue, Thomas Pottage, Constanze Yue, Jean-Clement Cabrol, Micaela Serafini, Iza Ciglenecki
Institution: Médecins Sans Frontières
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W2207983370